<DOC>
	<DOC>NCT02314611</DOC>
	<brief_summary>MicroPort Orthopedics (MPO) is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) and resurfacing components marketed in the European Union (EU). These types of studies are required by regulatory authorities for all THA and resurfacing devices that do not have medium to long-term clinical evidence available at the time of gaining approval to market in the EU. This study has been designed in accordance with the medial device directives (MEDDEV) 2.12/2 rev 2.</brief_summary>
	<brief_title>Post Market Clinical Follow-Up Study Protocol for PROFEMURÂ® Gladiator HA Coated Modular Femoral Stems</brief_title>
	<detailed_description />
	<mesh_term>Joint Diseases</mesh_term>
	<criteria>Subject has undergone primary THA for any of the following: Noninflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, ankylosis, protrusio acetabuli, or painful hip dysplasia; Inflammatory degenerative joint disease such as rheumatoid arthritis; or Correction of functional deformity Subject is implanted with the specified combination of components Subject is willing and able to complete required study visits or assessments Previously implanted bilateral subjects can have both THAs enrolled in the study provided: 1) the specified combination of components were implanted in both, 2) all other aspects of the Inclusion/Exclusion Criteria are satisfied, 3) enrollment does not exceed the subject count specified in the Investigator Agreement, and 4) the subject agrees to a second Informed Consent document specific to the second THA. Prospective enrollment of a previously unimplanted hip is not permitted in this study. Subjects skeletally immature (less than 21 years of age) at time of primary THA surgery Subjects currently enrolled in another clinical study Subjects unwilling to sign the Informed Consent document Subjects with substance abuse issues Subjects who are incarcerated</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>osteoarthritis</keyword>
	<keyword>avascular necrosis</keyword>
	<keyword>ankylosis</keyword>
	<keyword>protrusio acetabuli</keyword>
	<keyword>painful hip dysplasia</keyword>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>correction of functional deformity</keyword>
	<keyword>revision procedures</keyword>
</DOC>